284 related articles for article (PubMed ID: 17723299)
21. H+/K+-ATPase inhibitors: a patent review.
Li H; Meng L; Liu F; Wei JF; Wang YQ
Expert Opin Ther Pat; 2013 Jan; 23(1):99-111. PubMed ID: 23205582
[TBL] [Abstract][Full Text] [Related]
22. Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).
Bailey N; Bamford MJ; Brissy D; Brookfield J; Demont E; Elliott R; Garton N; Farre-Gutierrez I; Hayhow T; Hutley G; Naylor A; Panchal TA; Seow HX; Spalding D; Takle AK
Bioorg Med Chem Lett; 2009 Jul; 19(13):3602-6. PubMed ID: 19467868
[TBL] [Abstract][Full Text] [Related]
23. N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.
Mori H; Tonai-Kachi H; Ochi Y; Taniguchi Y; Ohshiro H; Takahashi N; Aihara T; Hirao A; Kato T; Sakakibara M; Kurebayashi Y
J Pharmacol Exp Ther; 2009 Feb; 328(2):671-9. PubMed ID: 18981288
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and antisecretory activity of 6-substituted 5-cyanomethylimidazo[2,1-b]thiazoles and 2,6-dimethyl-5-hydroxymethylimidazo[2,1-b][1,3,4]thiadiazole.
Andreani A; Leoni A; Locatelli A; Morigi R; Rambaldi M; Simon WA; Senn-Bilfinger J
Arzneimittelforschung; 2000 Jun; 50(6):550-3. PubMed ID: 10918949
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000.
Smolka AJ; Goldenring JR; Gupta S; Hammond CE
BMC Gastroenterol; 2004 Feb; 4():4. PubMed ID: 15028114
[TBL] [Abstract][Full Text] [Related]
26. IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.
Buckley GM; Ceska TA; Fraser JL; Gowers L; Groom CR; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
Bioorg Med Chem Lett; 2008 Jun; 18(11):3291-5. PubMed ID: 18482836
[TBL] [Abstract][Full Text] [Related]
27. Biochemical and pharmacological characteristics of a newly synthesized H+-K+ ATPase inhibitor, YJA20379-1, 2-amino-4,5-dihydro-8-phenylimidazole[2,1-b]thiazolo[5,4-g]benzothiazol e.
Sohn SK; Chang MS; Choi WS; Kim KB; Woo TW; Lee SB; Chung YK
Can J Physiol Pharmacol; 1999 May; 77(5):330-8. PubMed ID: 10535682
[TBL] [Abstract][Full Text] [Related]
28. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.
Shin JM; Cho YM; Sachs G
J Am Chem Soc; 2004 Jun; 126(25):7800-11. PubMed ID: 15212527
[TBL] [Abstract][Full Text] [Related]
29. Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers.
Nishida H; Hasuoka A; Arikawa Y; Kurasawa O; Hirase K; Inatomi N; Hori Y; Sato F; Tarui N; Imanishi A; Kondo M; Takagi T; Kajino M
Bioorg Med Chem; 2012 Jun; 20(12):3925-38. PubMed ID: 22579619
[TBL] [Abstract][Full Text] [Related]
30. Reversible and potent uncoupling of hog gastric (H(+)+K(+))-ATPase by prodigiosins.
Matsuya H; Okamoto M; Ochi T; Nishikawa A; Shimizu S; Kataoka T; Nagai K; Wasserman HH; Ohkuma S
Biochem Pharmacol; 2000 Dec; 60(12):1855-63. PubMed ID: 11108801
[TBL] [Abstract][Full Text] [Related]
31. Omeprazole has a dual mechanism of action: it inhibits both H(+)K(+)ATPase and gastric mucosa carbonic anhydrase enzyme in humans (in vitro and in vivo experiments).
Puscas I; Coltau M; Baican M; Domuta G
J Pharmacol Exp Ther; 1999 Aug; 290(2):530-4. PubMed ID: 10411559
[TBL] [Abstract][Full Text] [Related]
32. Studies on the mechanism of action of the gastric H+,K(+)-ATPase inhibitor SPI-447.
Tsukimi Y; Ushiro T; Yamazaki T; Ishikawa H; Hirase J; Narita M; Nishigaito T; Banno K; Ichihara T; Tanaka H
Jpn J Pharmacol; 2000 Jan; 82(1):21-8. PubMed ID: 10874584
[TBL] [Abstract][Full Text] [Related]
33. Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines.
Kaminski JJ; Bristol JA; Puchalski C; Lovey RG; Elliott AJ; Guzik H; Solomon DM; Conn DJ; Domalski MS; Wong SC
J Med Chem; 1985 Jul; 28(7):876-92. PubMed ID: 4009611
[TBL] [Abstract][Full Text] [Related]
34. Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.
Kaminski JJ; Puchalski C; Solomon DM; Rizvi RK; Conn DJ; Elliott AJ; Lovey RG; Guzik H; Chiu PJ; Long JF
J Med Chem; 1989 Aug; 32(8):1686-700. PubMed ID: 2754693
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).
Panchal T; Bailey N; Bamford M; Demont E; Elliott R; Farre-Gutierrez I; Garton N; Hayhow T; Hutley G; Naylor A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6813-7. PubMed ID: 19846298
[TBL] [Abstract][Full Text] [Related]
36. Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog.
Abelö A; Andersson M; Holmberg AA; Karlsson MO
Eur J Pharm Sci; 2006 Oct; 29(2):91-101. PubMed ID: 16831536
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of gastric H+,K+-ATPase activity by flavonoids, coumarins and xanthones isolated from Mexican medicinal plants.
Reyes-Chilpa R; Baggio CH; Alavez-Solano D; Estrada-Muñiz E; Kauffman FC; Sanchez RI; Mesia-Vela S
J Ethnopharmacol; 2006 Apr; 105(1-2):167-72. PubMed ID: 16314059
[TBL] [Abstract][Full Text] [Related]
38. Reversible inhibitors of the gastric (H+/K+)-ATPase as both potential therapeutic agents and probes of pump function.
Pope AJ; Sachs G
Biochem Soc Trans; 1992 Aug; 20(3):566-72. PubMed ID: 1330781
[No Abstract] [Full Text] [Related]
39. Mechanism of the inhibition of hog gastric H+,K(+)-ATPase by the seleno-organic compound ebselen.
Tabuchi Y; Ogasawara T; Furuhama K
Arzneimittelforschung; 1994 Jan; 44(1):51-4. PubMed ID: 8135879
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).
Arikawa Y; Nishida H; Kurasawa O; Hasuoka A; Hirase K; Inatomi N; Hori Y; Matsukawa J; Imanishi A; Kondo M; Tarui N; Hamada T; Takagi T; Takeuchi T; Kajino M
J Med Chem; 2012 May; 55(9):4446-56. PubMed ID: 22512618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
